Targeting B cell responses in universal influenza vaccine design

Trends in Immunology

Volumn 32, Issue 11, 2011, Pages 524-531

  Kaur, Kaval ^a   Sullivan, Meghan ^a   Wilson, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HN PROTEIN; INFLUENZA VACCINE; KEYHOLE LIMPET HEMOCYANIN; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; DRUG DESIGN; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; INFECTION RISK; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NONHUMAN; REVIEW; SEASONAL INFLUENZA; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRION; VIRUS NEUTRALIZATION;

ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 82455181387     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.08.007     Document Type: Review

References (57)

1. Beigel J.H. Influenza. Crit. Care Med. 2008, 36:2660-2666.
2. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 2007, 7:267-278.
3. Poland G.A., et al. Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis. 2009, 48:1254-1256.
4. Barr I.G., et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2010, 28:1156-1167.
5. Carrat F., Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
6. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
7. Wei C.J., et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Translational Med. 2010, 2:24ra21.
8. Kilbourne E.D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 2006, 12:9-14.
9. Swerdlow D.L., et al. 2009 H1N1 influenza pandemic: field and epidemiologic investigations in the United States at the start of the first pandemic of the 21(st) century. Clin. Infect. Dis. 2011, 52:S1-S3.
10. Kuehn B.M. H1N1 Vaccine. JAMA 2009, 302. 375-375.
11. Corti D., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010, 120:1663-1673.
12. Wrammert J., et al. Rapid cloning of high affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
13. Chen W.H., et al. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009, 30:351-359.
14. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem. 2000, 69:531-569.
15. Whittle J.R., et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14216-14221.
16. Wrammert J., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208:181-193.
17. Imai M., et al. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res. 1998, 53:129-139.
18. Ekiert D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
19. Sui J.H., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
20. Wei C.J., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064.
21. Steel J., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. Mbio 2010, 1. e00018-10.
22. Sui J., et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 2011, 52:1003-1009.
23. Wang T.T., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6:e1000796.
24. Hashem A.M., et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem. Biophys. Res. Commun. 2010, 403:247-251.
25. Ekiert D.C., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 10.1126/science.1204839.
26. Corti D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
27. Webster R.G., Laver W.G. Preparation and properties of antibody directed specifically against neuraminidase of influenza virus. J. Immunol. 1967, 99:49-55.
28. Monto A.S., Kendal A.P. Effect of neuraminidase antibody on Hong-Kong Influenza. Lancet 1973, 1:623-625.
29. Nimmerjahn F., Ravetch J.V. Antibody-mediated modulation of immune responses. Immunol. Rev. 2010, 236:265-275.
30. Jegerlehner A., et al. Influenza a vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172:5598-5605.
31. Mozdzanowska K., et al. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254:138-146.
32. Wang R.F., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008, 80:168-177.
33. Yu X.C., et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455:532-541.
34. Krause J.C., et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J. Virol. 2010, 84:3127-3130.
35. Xu R., et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328:357-360.
36. Hancock K., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 2009, 361:1945-1952.
37. Medina R.A., et al. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat. Commun. 2010, 1. 10.1038/ncomms1026.
38. Manicassamy B., et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 2010, 6:e1000745.
39. Khurana S., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 2011, 3:85ra48.
40. Wang T.T., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18979-18984.
41. Bommakanti G., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13701-13706.
42. Okuno Y., et al. A common neutralizing epitope conserved between the hemagglutinins of influenza-A virus H1 AND H2 strains. J. Virol. 1993, 67:2552-2558.
43. Throsby M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM(+) memory B cells. PloS ONE 2008, 3:e3942.
44. Sakabe S., et al. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res. 2010, 88:249-255.
45. Grandea A.G., et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12658-12663.
46. Zhao G.Y., et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol. J. 2010, 7:6.
47. Klenk H.D., et al. Activation of influenza-A viruses by trypsin treatment. Virology 1975, 68:426-439.
48. Skehel J.J., Waterfield M.D. Studies on primary structure of influenza-virus hemagglutinin. Proc. Natl. Acad. Sci. U.S.A. 1975, 72:93-97.
49. Lazarowitz S.G., Choppin P.W. Enhancement of infectivity of influenza-A and influenza-B viruses by proteolytic cleavage of hemagglutinin polypeptide. Virology 1975, 68:440-454.
50. Weis W., et al. Structure of the influenza-virus hemagglutinin complexed with its receptor, sialic-acid. Nature 1988, 333:426-431.
51. Cross K.J., et al. Composition and functions of the influenza fusion peptide. Protein Pept. Lett. 2009, 16:766-778.
52. Daniels R.S., et al. Fusion mutants of the influenza-virus hemagglutinin glycoprotein. Cell 1985, 40:431-439.
53. Skehel J.J., et al. Changes in the conformation of influneza-virus hemagglutinin at the pH optimum of virus-mediated membrane-fusion. Proc. Natl. Acad. Sci. U.S.A. Biol. Sci. 1982, 79:968-972.
54. Varghese J.N., et al. Structure of the influneza-virus glycoprotein antigen neuraminidase at 2.9-A-resolution. Nature 1983, 303:35-40.
55. Burmeister W.P., et al. THE 2.2-A resolution crystal-structure of influenza-B neuraminidase and its complex with sialic-acid. EMBO J. 1992, 11:49-56.
56. Huang I.C., et al. Influenza A virus neuraminidase limits viral superinfection. J. Virol. 2008, 82:4834-4843.
57. Colman P.M. Structural basis of antigenic variation - studies of influenza-virus neuraminidase. Immunol. Cell Biol. 1992, 70:209-214.